We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MCO:NYSEMoody's Corporation Analysis

Data as of 2026-05-21 - not real-time

$444.27

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Moody's Corporation posted $7.87 bn of revenue with an 8.1% YoY growth rate and ultra‑high profitability—gross margin of 74% and operating margin of 45%—driving an exceptional ROE of 71% despite a leveraged balance sheet. The company generated $3.08 bn of operating cash flow and $2.27 bn of free cash flow, comfortably covering its 27.6% dividend payout and supporting the 0.93% yield. However, the stock trades at a forward PE of 23.9x versus an industry average of 16.7x and a price‑to‑book of 25.9x, while the DCF model suggests a fair value near $201, indicating the market is pricing a significant premium. Technical indicators are mixed: the price of $444 sits below the 20‑day SMA ($449) but above the 50‑day SMA ($444), the RSI is neutral at 48.8, and the MACD is bearish, placing short‑term momentum on the downside, though the broader trend remains neutral with support at $426 and resistance at $470. Analyst sentiment is bullish, with a “buy” consensus, a median price target of $533 and an implied upside of roughly 20%, reinforced by recent earnings beat and a dividend increase. Material news highlights continued confidence from high‑profile investors, a recent analyst target cut by Mizuho after the earnings beat, and the upcoming dividend payment, all of which add short‑term catalyst potential.
Overall, Moody's combines a resilient, high‑margin business and strong cash generation with a premium valuation and modest short‑term technical weakness, suggesting a buy‑and‑hold approach for investors seeking growth‑oriented exposure with dividend income.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD and price below 20‑day SMA
  • Proximity to support at $426
  • Upcoming dividend provides near‑term income

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong earnings growth and high margins
  • Analyst consensus upside of ~20%
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Durable franchise with recurring credit‑rating and analytics revenue
  • High ROE and cash‑flow generation supporting long‑term value
  • Enduring confidence from investors like Warren Buffett

Key Metrics & Analysis

Financial Health

Revenue Growth8.10%
Profit Margin31.69%
P/E Ratio31.8
ROE71.36%
ROA14.82%
Debt/Equity235.54
P/B Ratio25.9
Op. Cash Flow$3.1B
Free Cash Flow$2.3B
Industry P/E16.7

Technical Analysis

TrendNeutral
RSI48.8
Support$426.21
Resistance$470.64
MA 20$449.41
MA 50$443.73
MA 200$479.53
MACDBearish
VolumeStable
Fear & Greed Index90.13

Valuation

Fair Value$200.96
Target Price$536.00
Upside/Downside20.65%
GradeOvervalued
TypeBlend
Dividend Yield0.93%

Risk Assessment

Beta0.78
Volatility27.19%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.